[go: up one dir, main page]

WO1993018026A1 - Uree d'indole agissant comme antagonistes au niveau des recepteurs de la 5-ht¿1c? - Google Patents

Uree d'indole agissant comme antagonistes au niveau des recepteurs de la 5-ht¿1c? Download PDF

Info

Publication number
WO1993018026A1
WO1993018026A1 PCT/GB1992/000381 GB9200381W WO9318026A1 WO 1993018026 A1 WO1993018026 A1 WO 1993018026A1 GB 9200381 W GB9200381 W GB 9200381W WO 9318026 A1 WO9318026 A1 WO 9318026A1
Authority
WO
WIPO (PCT)
Prior art keywords
urea
indol
methyl
pyridyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1992/000381
Other languages
English (en)
Inventor
Ian Thomson Forbes
Roger Thomas Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Priority to PCT/GB1992/000381 priority Critical patent/WO1993018026A1/fr
Publication of WO1993018026A1 publication Critical patent/WO1993018026A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to compounds having pharmacological activity, to a process for their preparation, to
  • compositions containing them and to their use in the treatment of mammals are provided.
  • 5HT 1C receptor antagonists are believed to be of potential use in the treatment of CNS disorders such as anxiety, depression, obsessive compulsive disorders, migraine, anorexia, Alzheimers disease, sleep disorders, bulimia, panic attacks, withdrawal from drug abuse and/or schizophrenia.
  • the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof:
  • R 1 , R 2 and R 3 are independently hydrogen or C 1-6 alkyl
  • R 4 is hydrogen, C 1-6 alkyl, halogen, hydroxy or NR 8 R 9 where R 8 and R 9 are independently hydrogen or C 1-6 alkyl;
  • R 5 and R 6 are independently hydrogen or C 1-6 alkyl; and R-y is hydrogen, C 1-6 alkyl or halogen; and wherein the urea moiety is attached at the 4-, 5- or 6-position of the indole ring.
  • Alkyl moieties within the variables R 1 to R 9 are preferably C 1-3 alkyl, such as methyl, ethyl, n- and iso- propyl, most preferably methyl, ethyl and n-propyl.
  • Suitable R 4 and R 7 halogens include chloro and bromo.
  • R 1 include hydrogen, methyl, ethyl and n-propyl, preferably methyl.
  • R 2 is preferably methyl or hydrogen and R 3 is hydrogen, methyl, ethyl, n-propyl, iso-propyl or
  • R 4 is hydrogen, chloro, hydroxy or dimethylamino, most preferably hydrogen.
  • R 5 , R 6 and R 7 are independently hydrogen or methyl.
  • the urea moiety may be attached at the 2-, 3-, 4-, 5- or 6-position of the pyridine ring, preferably the 3-, 4- or 5-position.
  • the urea moiety is preferably attached at the 4- or
  • the compounds of the formula (I) can form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric,
  • R 5 and/or R 6 are hydrogen or when R 4 is 2- or 4-hydroxy or NR 8 R 9 and at least one of Rg and Rg are hydrogen the compounds of formula (I) may exist tautomerically in more than one form.
  • the invention extends to each of these forms and mixtures thereof.
  • Certain compounds of formula (I) are capable of existing in stereoisomeric forms including enantiomers and the invention extends to each of these stereoisomeric forms and to
  • stereoisomeric forms may be separated one from the other by the usual methods, or any given isomer may be obtained by stereospecific or asymmetric synthesis.
  • the present invention also provides a process for the preparation of a compound of formula (I) or a
  • B is attached at the 4-, 5- or 6-position of the indole ring and A and B contain the appropriate functional group (s) necessary to form the moiety -NR 5 'CONR 6 '- when coupled, wherein R 5 ' and R 6 ' are R 5 and R6 as defined in formula (I) or groups convertible thereto, and the variables R 1 ', R 2 ' , R 3 ', R 4 ' and R 7 ' are R 1 , R 2 , R 3 , R 4 and R 7
  • R 4 ', R 5 ', R 6 ' and R 7 ' are as defined in formulae (II) and (III) and C and D contain the appropriate
  • A is -NR 5 'COL and B is -NHR 6 ',
  • A is -NHR 5 ' and B is -NR 6 'COL, or
  • A is halogen and B is -NR 6 'CONHR 5 ' ,
  • R 5 ' and R 6 ' are as defined above and L is a leaving group.
  • suitable leaving groups L include halogen such as chloro or bromo, imidazole, or phenoxy or phenylthio optionally substituted for example with halogen.
  • reaction is suitably carried out in an inert solvent for example dichloromethane or toluene at ambient temperature.
  • reaction is suitably carried out in an inert solvent such as dichloromethane at ambient temperature optionally in the presence of a base, such as triethylamine or in dimethylformamide at ambient or elevated temperature.
  • an inert solvent such as dichloromethane at ambient temperature
  • a base such as triethylamine or in dimethylformamide at ambient or elevated temperature.
  • reaction is suitably carried out in an inert solvent such as toluene at elevated temperature, optionally in the presence of a base.
  • an inert solvent such as toluene at elevated temperature, optionally in the presence of a base.
  • the cyclisation of the compound of formula (IV) may be effected using standard methodology such as described in Comprehensive Heterocyclic Chemistry 1984 4., 313 et. seq, or J. Het. Chem. 1988 25 p.l et seq.
  • Examples of the more important routes include the Leimgruber synthesis, the Fischer synthesis and the Japp-Klingemann variation and the Madelung synthesis.
  • groups C and D thus include
  • reaction variant (vi) (Leimgruber synthesis) the compound of formula (IV) is prepared from the 2-methylnitrophenyl urea by treatment with a dialkylacetal of the
  • reaction variant (vii) Fischer synthesis
  • the compound of formula (IV) is prepared from the hydrazinophenyl urea by dehydration, preferably by heating, with the appropriate ketone R 2 'COCH 2 R 3 ' and the product of formula (IV) cyclised by hesxing with an acid catalyst such as hydrochloric or sulphuric acid.
  • reaction variant (viii) Japp-Klingemann synthesis
  • the compound of formula (IV) is prepared from the aminophenyl urea by diazotisation followed by treatment for example with CH 3 COCH(CO 2 X)-CH 2 R 3 ' where X is C 1-6 alkyl under basic conditions in aqueous alcohol as solvent.
  • the product of formula (IV) may then be cyclised as in the Fischer synthesis above.
  • reaction variant (ix) (Madelung synthesis) the compound of formula (IV) is cyclised with base in an inert solvent optionally with heating.
  • Suitable examples of groups R 2 ', R 3 ', R 4 ', and R 7 ' which are convertible to R 2 , R 3 , R 4 , and R 7 respectively, include acyl groups which are introduced conventionally and may be converted to the corresponding alkyl group by conventional reduction, such as using sodium borohydride in an inert solvent followed by hydrogenolysis in an inert solvent and alkoxycarbonyl groups which may be converted to hydrogen by hydrolysis and decarboxylation.
  • R 4 is hydroxy ,it is preferably protected in the compound of formula (II) as, for example, an aryloxy group such as benzyloxy which is removed by hydrogenation.
  • Suitable examples of a group R 1 ' which is convertible to R 1 include typical N-protecting groups such as alkoxycarbonyl, in particular t-butyloxycarbonyl, acetyl, trifluoroacetyl, benzyl and para-methoxybenzyl which are converted to R 1 hydrogen using conventional conditions.
  • convertible to R 5 and R 6 respectively include alkoxycarbonyl and benzyl or para-methoxybenzyl which are converted to R 5 and/or R 6 hydrogen using conventional conditions.
  • Interconversions of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are carried out by conventional procedures.
  • R 1 , R 2 and R 3 are C 1-6 alkyl and R 5 and R 6 are hydrogen it is possible to introduce a C 1-6 alkyl group at both the R 5 and Rg positions by conventional alkylation using 2 molar equivalents of a C 1-6 alkyl halide and 2 molar equivalents of a suitable base in an inert solvent.
  • Monoalkylation can be achieved using 1 molar equivalent of a C 1-6 alkyl halide and base using conventional conditions.
  • R 1 C 1-6 alkyl groups may also be introduced by conventional alkylation, for example using a C 1-6 alkyl halide and base such as sodium hydride.
  • R 4 halo and R 7 halo may be introduced by selective
  • Compounds of formula (II) in which A is NHR 5 ' are known compounds or can be prepared analogously to known compounds.
  • the compounds of formula (II) in which A is 3-amino and R 4 ' is hydrogen, 2-chloro or 6-chloro, and A is 2-amino and R 4 ' is 3-benzyloxy are commercially available from the Aldrich Chemical Company in the UK.
  • R 5 ' C 1-6 alkyl groups may be introduced conventionally, for example by reductive alkylation or acylation and reduction.
  • Compounds of formula (II) in which A is -NR 5 'COL may be prepared by reacting a compound of formula (II) in which A is -NHR 5 ' with phosgene or a phosgene equivalent, in an inert solvent, at low temperature, if necessary in the presence of one equivalent of a base such as triethylamine.
  • Compounds of formula (II) in which A is halogen and R 4 ' is hydrogen are commercially available.
  • nitroindoles are commercially available, for example 5-nitroindole, or may be prepared conventionally
  • R 2 ' alkoxycarbonyl group may be eliminated to give R 2 ' hydrogen, generally under the conditions effecting formation of the nitroindole or as a subsequent step in the process.
  • Rg' alkyl groups may be introduced conventionally, for example by reductive alkylation or acylation and reduction.
  • R 7 ' C 1-6 alkyl groups may be introduced ortho to a nitro substituent by alkylation using a procedure similar to that described in G. Bartoli et. al., J. Org. Chem. 198651 3694 and Tetrahedron 1987 43 4221.
  • Compounds of formula (III) in which B is -NR 6 'COL may be prepared by reacting a compound of formula (III) in which B is -NHR 6 ' with phosgene or a phosgene equivalent, in an inert solvent, at low temperature, if necessary in the presence of one equivalent of a base such as triethylamine.
  • phosgene equivalents examples include triphosgene, carbonyldiimidazole, phenyl chloroformate and phenyl
  • Novel intermediates of formula (III) also form part of the invention.
  • Compounds of formula (IV) may be prepared from the
  • acceptable salts have 5HT 1C receptor antagonist activity and are believed to be of potential use in the treatment or prophylaxis of anxiety, depression, migraine, anorexia, obsessive compulsive disorders, Alzheimer's disease, sleep disorders, bulimia, panic attacks, withdrawal from drug abuse and/or schizophrenia.
  • the invention further provides a method of treatment or prophylaxis of anxiety, depression, migraine, anorexia, obsessive compulsive disorders, Alzheimer's disease, sleep disorders, bulimia, panic attacks, withdrawal from drug abuse and/or schizophrenia in mammals including humans, which comprises administering to the sufferer a
  • the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of anxiety, depression, migraine, anorexia, obsessive compulsive disorders, Alzheimer's disease, sleep disorders, bulimia, panic attacks, withdrawal from drug abuse and/or schizophrenia.
  • the present invention also provides a pharmaceutical
  • composition which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a
  • a pharmaceutical composition of the invention which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral,
  • parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusable solutions or suspensions or
  • compositions are generally preferred.
  • Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants,
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for
  • liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colourants.
  • fluid unit dosage forms are prepared utilising a compound of the invention or
  • concentration used can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration.
  • the compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • the composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.
  • suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 20.0 mg, for example 0.2 to 5 mg; and such unit doses may be administered more than once a day, for example two or three a day, so that the total daily dosage is in the range of about 0.01 to 100 mg/kg; and such therapy may extend for a number of weeks or months.
  • the title compound was prepared from 3-pyridinecarbonyl azide in toluene using a procedure similar to that described by L.S. Trifonov et al in Helv. Chim. Acta, 1987, 70, 262.
  • reaction mixture was then quenched with water, and poured onto excess water with stirring.
  • N-(1-Methyl-1H-indol-5-yl)formamide (D14) To acetic anhydride (1.68 ml; 15 mM) at 0°C was added 98% formic acid (0.8 ml; 21 mM) dropwise under a nitrogen atmosphere, to generate acetic formic anhydride. The solution was heated at 50-60°C for 2h then cooled to room temperature. Dichloromethane (2 ml) was added and the solution was cooled to -20°C before adding a solution of aminoindole (D3) (1g, 6.88 mM) in dichloromethane (4 ml). The mixture was stirred at room temperature for 17h then evaporated to dryness to give a brown oil (1.34g)
  • the title compound was prepared from 5-amino-1-methyl-1H-indole (D3), carbonyl diimidazole and 2-amino-3-benzyloxypyridine using a procedure similar to that
  • the title compound was prepared in 94% yield from the 4-nitrophenylhydrazone of 2-hexanone using the method of Fludzinski et al described in J.Med. Chem., 1986, .29, 2415.
  • Ethyl 2-Oxopentanoate (D28) The sodium salt of 2-oxopentanoic acid (1.00g, 7.25 mM) was taken up in water and acidified to pH 1. The solution was extracted with ethyl acetate (3 ⁇ 100 ml), dried and
  • the title compound was prepared in 62% yield from the 4-nitrophenyl hydrazone of 4-methyl-2-pentanone using the method of Fludzinski et al described in J. Med. Chem., 1986, 29, 2415.
  • the title compound was prepared from 5-amino-1-methyl-1H-indole (D3), phosgene and 3-aminopyridine using a
  • the title compound was prepared in 43% yield from 5-amino-1-propyl-1H-indole (D8) and 3-pyridyl isocyanate (D4) using a procedure similar to that in Example 2 (Method B), the product being isolated as the oxalate salt, m.p. 165-169°C.
  • Compound E7 may also be prepared by reacting 3-methyl-4-nitroaniline with 3-pyridyl isocyanate (D4) by the procedure of Method A.
  • the resulting nitrophenyl urea may be
  • the title compound was prepared from 1-methyl-5-methylamino- 1H-indole (D15) and 3-pyridyl isocyanate (D4) using a procedure similar to that described for Example 2 Method B.
  • the crude product was obtained in 45% yield. Recrystallisation from ethanol afforded the title compound, m.p. 168-170°C.
  • the title compound was prepared from 5-amino-1-methylindole (D3) and 2-aminopyridine using a procedure similar to that described for Example 8. The crude product was obtained in 83% yield. Recrystallisation from ethanol afforded the title compound in 70% yield, m.p. 182-185°C.
  • the title compound was prepared in 60% yield from 5-amino-1-methyl-1H-indole (D3), carbonyl diimidazole and 5-amino-2-chloropyridine, using a procedure similar to that described in Example 13. m.p. 212°C.
  • N-(1-Methyl-1H-indol-5-yl)-N'-(3-benzyloxypyrid-2-yl)urea (D18) (0.37g, 1 mM) was hydrogenated for 2h in ethanol (40 ml) at atmospheric pressure and room temperature. The reaction mixture was filtered through kieselguhr, washed with ethanol. The filtrate was evaporated in vacuo to afford the title compound (0.21g, 74%) which was converted to the hydrochloride salt using hydrogen chloride in ether. m.p. 223°C.
  • the title compound was prepared from the aminoindole (D21) and 3-pyridyl isocyanate (D4) using a procedure similar to that described for Example 2 Method B. The crude product was obtained in 79% yield. Recrystallisation from ethanol afforded the title compound, m.p. 192-193°C.
  • the title compound was prepared from the aminoindole (D27) and 3-pyridyl isocyanate (D4) using a procedure similar to that described for Example 2 Method B, the product being isolated as the free base.
  • the title compound was prepared from the aminoindole (D1), phosgene and 2-aminopyridine using a procedure similar to that described for Example 1, the product being isolated as the free base, m.p. 120-123°C.
  • the title compound was prepared in 47% yield from the aminoindole (Dl), phosgene and 4-aminopyridine using a procedure similar to that described for Example 1, the product being isolated as the hydrochloride salt, m.p. 237-243°C.
  • the title compound was prepared from the aminoindole (D38) and 3-pyridyl isocyanate (D4) using a procedure similar to that described for Example 2, Method B.
  • antagonists may have a number of therapeutic indications including the treatment of anxiety, migraine, depression, feeding disorders and obsessive compulsion disorders.
  • Alzheimer's Disease (Lawlor, 1989, J. Arch. Gen. Psychiat.
  • the affinity of test drugs for the 5-HT 1C binding site can be determined by assessing their ability to displace
  • [ 3 H]-mesulergine from 5-HT 1C binding sites in pig choroid plexus membranes The method employed was similar to that of Pazos et al, 1984. Pooled pig choroid plexi were homogenised in 20 vols of Tris HCl buffer (pH7.4) (containing 4mM CaCl 2 and 0.01% ascorbic acid) and centrifuged at 50,000g for 15 min at 4°C. The supernatant was removed and re-centrifuged. This was repeated a further two times with the incubation of the homogenate (37°C for 15 min) before the final
  • the tissue suspension (50 ⁇ l) was incubated with
  • Non-specific binding was measured in the presence of mianserin (10 -6 M).
  • Six concentrations of test drug (10 -9 to 10 -4 M final concentration) were added in a volume of 50 ⁇ l. The total assay volume was 500 ⁇ l.
  • Kd Affinity of mesulergine for 5-HT 1C binding sites.
  • 5-Hydroxytryptamine induces contractions of the rat stomach fundus through a 5-HT receptor that has the
  • Rat stomach strips (6 ⁇ 4mm) were suspended under a 4g tension in 5ml baths containing Tyrode solution, gassed with a mixture of 95% O 2 /5% CO 2 . After a 1 hour equilibration period, two dose response curves were constructed to 5-HT (final concentrations, 10 -9 to 3 ⁇ 10 -6 M). Test drugs were then incubated at a final concentration of 10 -6 M for 30 mins and another dose-response curve constructed to 5-HT.
  • Rats were housed in groups of 8 in a holding room adjacent to the experimental chamber for 8 days. They were then housed singly in the same room for 3 days prior to the experimental day. On the experimental day rats were
  • the compound of Example 2 showed a significant increase in social interaction at doses of 2-40 mg/kg.
  • Rats are trained on a variable interval 30 sec schedule (VI30) to press a lever in order to obtain food reward.
  • the 5 min sessions of the VI30 schedule alternate with 2-5 min of a schedule (FR5) in which every 5th lever press is followed by presentation of a food pellet paired with a 0.5 sec mild footshock.
  • the total study lasts approximately 30 mins.
  • Rats typically respond with high rates of lever pressing under the VI30 schedule and low response rates under the FR5 'conflict' session.
  • Anxiolytic drugs increase the suppressed response rates of rats in a 'conflict' session.
  • Drugs are administered intraperitoneally or orally to groups of 3-8 rats 30 min before testing.
  • the compound of Example 2 showed a significant increase in responding in the 'conflict' session at dose levels in the range 5-40 mg/kg p.o.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne les urées d'indole de la formule (I) et leurs sels acceptables sur le plan pharmaceutique. Dans cette formule, R1, R2 et R3 sont d'une manière indépendante un hydrogène ou un (C1-6)alkyle; R4 est un hydrogène, un (C1-6)alkyle, un halogène, un hydroxy ou un NR8R9 où R8 et R9 sont d'une manière indépendante un hydrogène ou un (C1-6)alkyle; R5 et R6 sont d'une manière indépendante un hydrogène ou un(C1-6)alkyle; et R7 est yn hydrogène, un (C1-6)alkyle ou un halogène; et la fraction urée est fixée en position 4, 5 ou 6 sur le noyau de l'indole. Ces composés agissent comme antagonistes au niveau des récepteurs de la 5-HT1C.
PCT/GB1992/000381 1992-03-04 1992-03-04 Uree d'indole agissant comme antagonistes au niveau des recepteurs de la 5-ht¿1c? Ceased WO1993018026A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/GB1992/000381 WO1993018026A1 (fr) 1992-03-04 1992-03-04 Uree d'indole agissant comme antagonistes au niveau des recepteurs de la 5-ht¿1c?

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB1992/000381 WO1993018026A1 (fr) 1992-03-04 1992-03-04 Uree d'indole agissant comme antagonistes au niveau des recepteurs de la 5-ht¿1c?

Publications (1)

Publication Number Publication Date
WO1993018026A1 true WO1993018026A1 (fr) 1993-09-16

Family

ID=10708310

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1992/000381 Ceased WO1993018026A1 (fr) 1992-03-04 1992-03-04 Uree d'indole agissant comme antagonistes au niveau des recepteurs de la 5-ht¿1c?

Country Status (1)

Country Link
WO (1) WO1993018026A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025012A3 (fr) * 1993-04-28 1994-12-22 Smithkline Beecham Plc Medicaments pour le traitement de la migraine, de l'epilepsie et des troubles de l'alimentation
WO2001000576A1 (fr) * 1999-06-29 2001-01-04 Ortho-Mcneil Pharmaceutical, Inc. Uree-peptoides de type indole et indazole utilises en tant qu'antagonistes du recepteur de thrombine
WO2001032619A1 (fr) * 1999-11-03 2001-05-10 Astrazeneca Ab Modulateurs positifs des agonistes du recepteur nicotinique
WO2001032622A1 (fr) * 1999-11-03 2001-05-10 Astrazeneca Ab Modulateurs positifs d'agonistes de recepteur nicotinique
US6630451B1 (en) 1999-06-29 2003-10-07 Orthomcneil Pharmaceutical, Inc. Benzimidazolone peptidometics as thrombin receptor antagonist
WO2003087087A3 (fr) * 2002-04-09 2003-12-18 Astex Technology Ltd Composes pharmaceutiques
US6858577B1 (en) 1999-06-29 2005-02-22 Ortho-Mcneil Pharmaceutical, Inc. Indole peptidomimetics as thrombin receptor antagonists
US6967216B2 (en) 2000-05-05 2005-11-22 Astrazeneca Ab Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor
US7049297B2 (en) 1999-06-29 2006-05-23 Ortho-Mcneil Pharmaceutical, Inc. Indazole peptidomimetics as thrombin receptor antagonists
US7408064B2 (en) 2001-09-11 2008-08-05 Astrazeneca Ab Carbazole derivatives and their use as NPY5 receptor antagonists
FR2926077A1 (fr) * 2008-01-04 2009-07-10 Servier Lab Nouveaux derives d'1h-indol-1-yl uree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005170A1 (fr) * 1990-09-13 1992-04-02 Beecham Group Plc Urees d'indole utilisees comme antagonistes de recepteur de 5-ht

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005170A1 (fr) * 1990-09-13 1992-04-02 Beecham Group Plc Urees d'indole utilisees comme antagonistes de recepteur de 5-ht

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF MEDICINAL CHEMISTRY, vol. 29, no. 11, 1986, WASHINGTON (US) pages 2415 - 2418, P. FLUDZINSKI: "2,3-Dialkyl (dimethylamino) indoles: interaction with 5HT1, 5HT2, and rat stomach fundal serotonin receptors." *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025012A3 (fr) * 1993-04-28 1994-12-22 Smithkline Beecham Plc Medicaments pour le traitement de la migraine, de l'epilepsie et des troubles de l'alimentation
US6943149B2 (en) 1999-06-29 2005-09-13 Ortho Mcneil Pharmaceutical, Inc. Benzimidazolone peptidomimetics as thrombin receptor antagonists
WO2001000576A1 (fr) * 1999-06-29 2001-01-04 Ortho-Mcneil Pharmaceutical, Inc. Uree-peptoides de type indole et indazole utilises en tant qu'antagonistes du recepteur de thrombine
US7183252B2 (en) 1999-06-29 2007-02-27 Ortho-Mcneil Pharmaceutical, Inc. Indole peptidomimetics as thrombin receptor antagonists
US6365617B1 (en) 1999-06-29 2002-04-02 Ortho-Mcneil Pharmaceutical, Inc. Indole and indazole urea-peptoids as thrombin receptor antagonists
US6630451B1 (en) 1999-06-29 2003-10-07 Orthomcneil Pharmaceutical, Inc. Benzimidazolone peptidometics as thrombin receptor antagonist
US7049297B2 (en) 1999-06-29 2006-05-23 Ortho-Mcneil Pharmaceutical, Inc. Indazole peptidomimetics as thrombin receptor antagonists
US6858577B1 (en) 1999-06-29 2005-02-22 Ortho-Mcneil Pharmaceutical, Inc. Indole peptidomimetics as thrombin receptor antagonists
US7402604B2 (en) 1999-11-03 2008-07-22 Astrazeneca Ab Positive modulators of nicotinic receptor agonists
AU783507B2 (en) * 1999-11-03 2005-11-03 Astrazeneca Ab Positive modulators of nicotinic receptor agonists
US7064143B1 (en) 1999-11-03 2006-06-20 Astrazeneca Ab Positive modulators of nicotinic receptor agonists
WO2001032622A1 (fr) * 1999-11-03 2001-05-10 Astrazeneca Ab Modulateurs positifs d'agonistes de recepteur nicotinique
WO2001032619A1 (fr) * 1999-11-03 2001-05-10 Astrazeneca Ab Modulateurs positifs des agonistes du recepteur nicotinique
US6967216B2 (en) 2000-05-05 2005-11-22 Astrazeneca Ab Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor
US7332492B2 (en) 2000-05-05 2008-02-19 Astrazeneca Ab Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor
US7408064B2 (en) 2001-09-11 2008-08-05 Astrazeneca Ab Carbazole derivatives and their use as NPY5 receptor antagonists
WO2003087087A3 (fr) * 2002-04-09 2003-12-18 Astex Technology Ltd Composes pharmaceutiques
FR2926077A1 (fr) * 2008-01-04 2009-07-10 Servier Lab Nouveaux derives d'1h-indol-1-yl uree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
EP2078716A1 (fr) * 2008-01-04 2009-07-15 Les Laboratoires Servier Nouveaux dérivés d'1H-indol-1-yl urée, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
WO2009106753A1 (fr) * 2008-01-04 2009-09-03 Les Laboratoires Servier Nouveaux derives d'1h-indol-1-yl uree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Similar Documents

Publication Publication Date Title
AU642041B2 (en) Indole ureas as 5 HT receptor antagonist
US5508288A (en) Indole derivatives as 5HT1C antagonists
US6008231A (en) N-substituted indole-3 glyoxylamides having anti-asthmatic antiallergic and immunosuppressant/immuno-modulating action
DE60222396T2 (de) N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste
US7189739B2 (en) Compounds and methods to treat cardiac failure and other disorders
KR100605140B1 (ko) 심장병 및 다른 질병을 치료하기 위한 헤테로 고리 화합물및 그 치료 방법
KR100377696B1 (ko) 설파미드-메탈로프로테아제 억제제
HUT74090A (en) Indole derivatives, process for producing them and pharmaceutical compositions containing them
US6143760A (en) Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands
JPH08506114A (ja) ５ＨＴ▲下２▼ｃレセプター拮抗薬としてのフェニルヘテロアリール尿素の使用および尿素化合物
JP2001526643A (ja) ５ｈｔ１ａ、５ｈｔ１ｂおよび５ｈｔ１ｄ受容体アンタゴニスト活性を合わせ持つ化合物を含む二環式アリールまたは二環式複素環
EP0370498A2 (fr) Composés trans-4-amino(alcoyl)-1-pyridylcarbamoylcyclohexane et leur utilisation pharmaceutique
WO1993018026A1 (fr) Uree d'indole agissant comme antagonistes au niveau des recepteurs de la 5-ht¿1c?
WO1996011930A1 (fr) Derives de pyridinyluree actifs dans le traitement des troubles du systeme nerveux central
AU4704693A (en) Condensed indole derivatives as 5HT-2C and 5HT-2B antagonists
WO1997008167A1 (fr) Antagonistes des recepteurs 5ht2c et 5ht¿2b?
US4732900A (en) 1,2,4-triazolo-carbamates
US4792554A (en) Pyridine compounds, pharaceutical compositions, their use in allergy therapy
JPH03218356A (ja) トランス―４―アミノ（アルキル）―１―ピリジルカルバモイルシクロヘキサン化合物およびその医薬用途
NZ239744A (en) N-(indolyl)-n'-(pyridyl)ureas, intermediates and pharmaceutical compositions
KR900005034B1 (ko) 융합 비사이클릭 이미드 및 그의 제조방법
US3691176A (en) 1-(4-fluorophenoxypropyl)-4-anilino-piperidines
EP0743946A1 (fr) Indoles condenses a titre d'antagonistes des recepteurs de 5ht 2b?
WO1993016694A1 (fr) Utilisation d'indylpyridylurees pour traiter les effets d'un traumatisme du cerveau ou de la colonne vertebrale
HK1034707B (en) Heterocyclic compounds and methods to treat cardiac failure and other disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): BR CS FI HU NO PL